Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eribulin mesylate + pertuzumab + trastuzumab (Sun Yat-sen Memorial Hospital)
- Development stage
- Phase 3
- Lead developer
- Sun Yat-Sen Memorial Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of eribulin mesylate, pertuzumab, and trastuzumab. Eribulin mesylate is a non-taxane microtubule dynamics inhibitor that binds to high-affinity sites on the growing positive ends of microtubules, leading to irreversible mitotic block and apoptosis. Pertuzumab and trastuzumab are recombinant humanized monoclonal antibodies that target the human epidermal growth factor receptor 2 (HER2). Trastuzumab binds to domain IV of HER2, inhibiting ligand-independent signaling and mediating antibody-dependent cellular cytotoxicity (ADCC). Pertuzumab binds to domain II, preventing HER2 from dimerizing with other HER family members (HER1, HER3, HER4). This triplet combination is being investigated by Sun Yat-Sen Memorial Hospital as a neoadjuvant therapy for patients with HER2-positive early or locally advanced breast cancer to improve pathological complete response (pCR) rates.
- Other names
- eribulin + pertuzumab + trastuzumab
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on eribulin mesylate + pertuzumab + trastuzumab (Sun Yat-sen Memorial Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eribulin mesylate + pertuzumab + trastuzumab (Sun Yat-sen Memorial Hospital).